Squarepoint
ALNY icon

Squarepoint’s Alnylam Pharmaceuticals ALNY Stock Holding History

Squarepoint’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.1M Buy
12,400
+8,700
+235% +$2.96M ﹤0.01% 1648
2025
Q4 		$1.47M Sell
3,700
-4,800
-56% -$2.12M ﹤0.01% 2287
2025
Q3 		$3.88M Buy
8,500
+4,200
+98% +$1.71M ﹤0.01% 1612
2025
Q2 		$1.4M Sell
4,300
-500
-10% -$138K ﹤0.01% 2365
2025
Q1 		$1.3M Sell
4,800
-13,500
-74% -$3.47M ﹤0.01% 2440
2024
Q4 		$4.31M Buy
18,300
+14,700
+408% +$3.87M ﹤0.01% 1765
2024
Q3 		$990K Buy
3,600
+2,400
+200% +$625K ﹤0.01% 2613
2024
Q2 		$292K Sell
1,200
-18,800
-94% -$2.97M ﹤0.01% 3446
2024
Q1 		$2.99M Buy
+20,000
New +$3.34M 0.01% 1828
2021
Q3 		– Sell
-1,900
Closed -$322K – 2867
2021
Q2 		$322K Sell
1,900
-62,700
-97% -$9.18M ﹤0.01% 2475
2021
Q1 		$9.12M Buy
+64,600
New +$9.72M 0.05% 397

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's ALNY Position: Q1 2026 in Review

Squarepoint increased its Alnylam Pharmaceuticals (ALNY) stake by 22% in Q1 2026, buying an estimated $25.8M and bringing the position to 426,723 shares worth $141M. The position accounts for 0.17% of the portfolio, ranked #100.

Squarepoint first reported a position in ALNY in Q4 2015 and has held it in 33 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Squarepoint held 426,723 shares of Alnylam Pharmaceuticals worth $141M as of Q1 2026.
  • Squarepoint bought 75,754 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $25.8M.
  • Alnylam Pharmaceuticals made up 0.17% of Squarepoint's portfolio in Q1 2026, its #100 holding.
  • Squarepoint first reported a position in Alnylam Pharmaceuticals in Q4 2015 and has held it in 33 quarters since.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.